Richard White, COO of Oxford PharmaGenesis, was a panellist at the recent virtual workshop on ‘Artificial intelligence (AI) to accelerate discovery’, hosted by the Friends of the National Library of Medicine (FNLM) and sponsored by Oxford PharmaGenesis. He discussed emerging trends in the use of AI by the pharmaceutical industry, with a focus on how […]
As #MedicalCommunications and #Publications professionals, how do we bring diversity to our work and how do we achieve it? Today at #ISMPP17AM, our CEO @ChrisW_PharmaG joins a panel on 'Equity, diversity, and inclusion: defining a roadmap for our profession' 10am (EST)/3pm (BST) https://t.co/PxOijPTmh5
Medical Affairs drives many activities in pharma – but it can bring unique challenges. We're leading an @ISMPP session to help you develop #MedicalAffairs leadership skills and succeed in cross-collaboration. Visit here for more information: https://t.co/UMWOOs5UIt #ISMPP17AM https://t.co/8KCjRLIIz6
12th April 2021
Virtual 17th Annual Meeting of ISMPP
Oxford PharmaGenesis is sponsoring this year's meeting of International Society for Medical Publication Professionals (ISMPP). We're taking part in discussions and debates on evolving issues for HealthScience such as Open Access, preprint, and Artificial Intelligence.
Oxford PharmaGenesis has been recognized across offices worldwide with an internationally renowned UK Best WorkplacesTM award. The accreditation is thanks to colleagues who rated the leading independent HealthScience communications consultancy as ‘a great place to work’ in the Great Place to Work® 2021 survey.
Innovative AI-based open-source research tool to identify emerging oncology biomarkers in the scientific literature
Together with Pfizer Inc. and Digital Science, Oxford PharmaGenesis colleagues have co-developed an AI-based literature interrogation tool that will help researchers to identify biomarkers of emerging scientific interest in oncology.
Part-funded by Oxford PharmaGenesis, ‘Our Big MS Adventure’ uniquely shows the impact of multiple sclerosis over 12 years, highlighting breakthroughs in treatment, and sharing emotive personal journeys.
Richard White, COO of Oxford PharmaGenesis, provides his expert insights on health economics and outcomes research (HEOR) publications and open access in a new article from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the leading global professional society for HEOR.
Share this page Overview Day 1 report Oxford PharmaGenesis at the Virtual 17th Annual Meeting of ISMPP Company overview video ISMPP is a fantastic opportunity to share best practice and connect with people who share our vision for what medical publications and communications can achieve. Presentations April 12, 2021, 12:00 PM – 1:00 PM – […]